A Form 4 filed on September 9, 2026 discloses that Kevin Bitterman, a director of Disc Medicine, Inc. (NASDAQ:IRON), sold a combined 1,689 shares of common stock on September 4, 2026, through three Atlas Venture-affiliated funds under a pre-established Rule 10b5-1 trading plan.
Key Highlights
- Reporting person: Kevin Bitterman, serving as a director of Disc Medicine, Inc.
- Transaction date: September 4, 2026, with shares sold at a weighted average price of $79.96 per share, in multiple transactions ranging from $79.95 to $79.98 inclusive.
- Shares sold: 912 shares from Atlas Venture Opportunity Fund I, L.P.; 759 shares from Atlas Venture Opportunity Fund II, L.P.; and 18 shares from Atlas Venture Fund XII, L.P.
- Post-transaction holdings: 318,866 shares indirectly held through Atlas Venture Opportunity Fund I, L.P.; 312,230 shares through Atlas Venture Opportunity Fund II, L.P.; and 13,427 shares through Atlas Venture Fund XII, L.P.
- Trading plan: All sales were made pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026.
- Beneficial ownership disclaimer: Bitterman disclaims beneficial ownership of all shares held through the Atlas Venture entities, except to the extent of his pecuniary interest therein, if any.
Bitterman's Atlas Venture Sales in Disc Medicine Common Stock
According to the filing, Kevin Bitterman, a director at Disc Medicine, Inc., disposed of a total of 1,689 shares of common stock on September 4, 2026, across three separate transactions, each coded as a sale ("S"). All transactions were executed under a Rule 10b5-1 trading plan that Bitterman adopted on July 30, 2026. The filing notes the form was also checked to indicate the transactions were made pursuant to a contract, instruction, or written plan satisfying the affirmative defense conditions of Rule 10b5-1(c).
The shares were sold on behalf of three Atlas Venture-affiliated funds in which Bitterman holds membership interests in their respective general partner entities. Specifically, 912 shares were disposed of from Atlas Venture Opportunity Fund I, L.P., 759 shares from Atlas Venture Opportunity Fund II, L.P., and 18 shares from Atlas Venture Fund XII, L.P. All sales carried a weighted average price of $79.96, with individual transactions priced between $79.95 and $79.98, according to the filing. The filing states that full per-share transaction detail is available upon request to the issuer, any security holder, or SEC staff.
All reported holdings are indirect. The filing states that Bitterman "disclaims beneficial ownership of such securities" held by each of the three funds, except to the extent of his pecuniary interest therein, if any. No direct holdings of common stock or derivative securities were reported. The form was signed by Ommer Chohan as Attorney-in-Fact on September 9, 2026.
What Was Disclosed
Director Kevin Bitterman reported the sale of 1,689 total shares of Disc Medicine, Inc. common stock through three Atlas Venture funds on September 4, 2026, at a weighted average price of $79.96 per share, under a Rule 10b5-1 plan adopted July 30, 2026.






Please wait processing your request...